-
公开(公告)号：EP2914290B1
公开(公告)日：2020-04-01
申请号：EP13798590.9
申请日：2013-10-31
IPC分类号： A61K39/395 , C07K16/24
-
公开(公告)号：EP3331915A1
公开(公告)日：2018-06-13
申请号：EP16757165.2
申请日：2016-08-05
IPC分类号： C07K16/28 , G01N33/574 , A61K39/395 , A61P35/02
CPC分类号： C07K16/2851 , A61K39/0011 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/5156 , C07K14/7051 , C07K16/18 , C07K16/2803 , C07K16/2809 , C07K16/2896 , C07K2317/31 , C07K2317/62 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2319/74 , Y02A50/466
摘要： The present invention provides an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT for use in a method of treatment of a blood-borne cancer, in particular acute myeloid leukemia (AML). Moreover, the present invention provides a pharmaceutical composition comprising an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT and a CAR T cell. The present invention further provides a pharmaceutical composition comprising an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT and an antibody construct that is capable of engaging T cells.
-
公开(公告)号：EP3328893A1
公开(公告)日：2018-06-06
申请号：EP16757163.7
申请日：2016-08-01
发明人： RAUM, Tobias , KUFER, Peter , RAU, Doris , ANLAHR, Jonas , BLUEMEL, Claudia , HOFFMANN, Patrick , NAHRWOLD, Elisabeth , BAILIS, Julie
CPC分类号： C07K16/28 , C07K16/2809 , C07K16/30 , C07K2317/31 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2317/94
摘要： The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human MSLN on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
-
公开(公告)号：EP3328890A1
公开(公告)日：2018-06-06
申请号：EP16756951.6
申请日：2016-08-01
发明人： RAUM, Tobias , DEISTING, Wibke , BLUEMEL, Claudia , PANZER, Marc , HOFFMANN, Patrick , NAHRWOLD, Elisabeth , NOLAN-STEVAUX, Olivier , LUTTERBUESE, Ralf
摘要： The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human CD70 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
-
公开(公告)号：EP3018145B1
公开(公告)日：2018-04-04
申请号：EP15195076.3
申请日：2011-10-27
IPC分类号： C07K16/28 , C07K16/46 , A61K39/395 , A61P35/00
CPC分类号： C07K16/2809 , A61K39/39558 , A61K2039/505 , A61K2039/545 , C07K16/2803 , C07K2317/31 , C07K2317/76
摘要： The present invention provides means and methods for treating diffuse large B cell lymphoma (DLBCL). Specifically, a bispecific CD19 x CD3 antibody which engages T cells via its CD3 binding portion and concomitantly binds to CD19 on the surface of, in particular, lymphoma cells via its CD19 binding portion (i.e. a bispecific T cell engager, "BiTE") is administered for use in the treatment of tumorous mass of lymophoreticular tissue and/or extranodal lymphoma caused by DLBCL in a patient.
-
公开(公告)号：EP2918604B1
公开(公告)日：2017-12-20
申请号：EP15154416.0
申请日：2009-11-06
发明人： Zugmaier, Gerhard
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/2809 , C07K16/3061 , C07K16/468
摘要： The present invention relates to a method for the treatment, amelioration or elimination of pediatric acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19xCD3 bispecific single chain antibody construct to a pediatric ALL patient in the need thereof.
-
67.发明公开CROSS-SPECIES-SPECIFIC PSMAXCD3 BISPECIFIC SINGLE CHAIN ANTIBODY 审中-公开BISPEZIFISCHER EINKETTIGER PSMAXCD3-ANTIKÖRPERMITARTENÜBERGREIFENDERSPEZIFITÄT
公开(公告)号：EP3106468A1
公开(公告)日：2016-12-21
申请号：EP16167900.6
申请日：2009-10-01
发明人： KUFER, Peter , RAUM, Tobias , KISCHEL, Roman , LUTTERBUESE, Ralf , HOFFMANN, Patrick , RAU, Doris , MANGOLD, Susanne , KLINGER, Matthias , SCHALLER, Evelyne , HAUSMANN, Susanne , FLUHR, Petra , STEIGER, Carola
CPC分类号： C07K16/3069 , A61K2039/505 , C07K2317/31 , C07K2317/34
摘要： The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.
摘要翻译： 本发明涉及双特异性单链抗体分子，其包含能够结合人和非黑猩猩灵长类CD3ε链的表位的第一结合结构域，其中所述表位是包含在SEQ ID NO：1中的氨基酸序列的一部分 身份证号 2,4,6和8以及能够结合前列腺特异性膜抗原（PSMA）的第二结合结构域。 本发明还提供编码所述双特异性单链抗体分子的核酸以及载体和宿主细胞及其生产方法。 本发明还涉及包含所述双特异性单链抗体分子的药物组合物和所述双特异性单链抗体分子的医学应用。
-
68.发明授权
公开(公告)号：EP1940881B1
公开(公告)日：2016-11-30
申请号：EP06806155.5
申请日：2006-10-10
发明人： KISCHEL, Roman , RAUM, Tobias , SCHLERETH, Bernd , RAU, Doris , CIERPKA, Ronny , KUFER, Peter
IPC分类号： C07K16/28 , C07K16/30 , A61K39/395 , A61P35/00 , C12N15/13
CPC分类号： A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/2809 , C07K16/30 , C07K16/40 , C07K16/468 , C07K2317/31 , C07K2317/34 , C07K2317/56 , C07K2317/622
-
公开(公告)号：EP2970472A1
公开(公告)日：2016-01-20
申请号：EP14716251.5
申请日：2014-03-14
发明人： KUFER, Peter , RAUM, Tobias , HOFFMANN, Patrick , KISCHEL, Roman , LUTTERBUESE, Ralf , RAU, Doris , ADAM, Paul , BORGES, Eric , HEBEIS, Barbara , HIPP, Susanne
IPC分类号： C07K16/28
CPC分类号： C07K16/2878 , A61K2039/505 , C07K16/2809 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/622
摘要： The present invention relates to a binding molecule comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope clusters of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.
摘要翻译： 本发明涉及包含第一和第二结合结构域的结合分子，其中第一结合结构域能够结合BCMA的表位簇，并且第二结合结构域能够结合T细胞CD3受体复合物。 此外，本发明提供编码结合分子的核酸序列，包含所述核酸序列的载体和用所述载体转化或转染的宿主细胞。 此外，本发明提供了制备本发明的结合分子的方法，所述结合分子的医学用途和包含所述结合分子的试剂盒。
-
公开(公告)号：EP2279001B1
公开(公告)日：2015-09-30
申请号：EP09738147.9
申请日：2009-04-28
IPC分类号： A61K39/395 , A61P35/00 , A61P29/00 , C07K16/28 , C07K16/24 , A01K67/027
CPC分类号： C07K16/244 , A61K2039/507 , C07K16/243 , C07K2317/34 , C07K2317/76
-
-
-
-
-
-
-
-
-
搜索结果
123 条记录 (耗时 0.052 秒)
